GlassScriptPhysician profile
Dawn Kershner
NPI 1851394142
$827.41
in general payments reported to CMS, 2019-2025
14 companies · $533 in 2025
The $533 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.97 · 2024: $280 · 2025: $533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $812.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $812.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $171.10 | 2024 | Assure Wcd |
| Medtronic, INC. | $150.28 | 2025 | Symplicity G3 |
| Scpharmaceuticals INC. | $108.07 | 2025 | |
| Pfizer INC. | $81.05 | 2025 | |
| Atricure, INC. | $75.84 | 2019-2024 | |
| Baxter Healthcare | $75.37 | 2025 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.57 | 2025 | Jardiance |
| Amgen INC. | $24.59 | 2025 | Repatha |
| Merck Sharp & Dohme LLC | $22.63 | 2025 | Verquvo |
| Abbott Laboratories | $17.67 | 2024 | Jot Dx |
| Philips North America LLC | $16.49 | 2024 | (5091) Amb Mon & Diag Und |
| Bayer Healthcare Pharmaceuticals INC. | $16.11 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $14.85 | 2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $13.79 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dawn Kershner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.